Parameter
| Biomarker | RPL13 | Full name | Ribosomal Protein L13 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Imatinib resistance prediction |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Plasma (ultracentrifugation, LC-MS/MS, Western blot, PRM) | ||
| Pathobiological Mechanisms | Imatinib-resistant patients exhibit significantly upregulated exosomes in plasma, which are involved in protein synthesis regulation | ||||
| Clinical Availability Status | Research validation: Differentially expressed genes have been confirmed through multiple technical validations. | ||||
| Notes and Dynamics | To provide new insights into the mechanism of imatinib resistance, it serves as a potential biomarker for drug resistance. | ||||